204 related articles for article (PubMed ID: 20936459)
1. Non-small cell lung cancer in stages I-IIIB: Long-term results of definitive radiotherapy with doses ≥ 80 Gy in standard fractionation.
Wurstbauer K; Weise H; Deutschmann H; Kopp P; Merz F; Studnicka M; Nairz O; Sedlmayer F
Strahlenther Onkol; 2010 Oct; 186(10):551-7. PubMed ID: 20936459
[TBL] [Abstract][Full Text] [Related]
2. Nonresected non-small-cell lung cancer in Stages I through IIIB: accelerated, twice-daily, high-dose radiotherapy--a prospective Phase I/II trial with long-term follow-up.
Wurstbauer K; Deutschmann H; Kopp P; Kranzinger M; Merz F; Nairz O; Studnicka M; Sedlmayer F
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1345-51. PubMed ID: 19910140
[TBL] [Abstract][Full Text] [Related]
3. DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)--a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume.
Wurstbauer K; Deutschmann H; Dagn K; Kopp P; Zehentmayr F; Lamprecht B; Porsch P; Wegleitner B; Studnicka M; Sedlmayer F
Radiat Oncol; 2013 Mar; 8():49. PubMed ID: 23497555
[TBL] [Abstract][Full Text] [Related]
4. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.
Rosenman JG; Halle JS; Socinski MA; Deschesne K; Moore DT; Johnson H; Fraser R; Morris DE
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):348-56. PubMed ID: 12243807
[TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial.
Pöttgen C; Eberhardt W; Bildat S; Stüben G; Stamatis G; Hillejan L; Sohrab S; Teschler H; Seeber S; Sack H; Stuschke M
Ann Oncol; 2002 Mar; 13(3):403-11. PubMed ID: 11996471
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional conformal radiation therapy for non-small-cell lung cancer: a phase I/II dose escalation clinical trial.
Wu KL; Jiang GL; Liao Y; Qian H; Wang LJ; Fu XL; Zhao S
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1336-44. PubMed ID: 14630271
[TBL] [Abstract][Full Text] [Related]
7. DART-bid for loco-regionally advanced NSCLC : Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints.
Wurstbauer K; Zehentmayr F; Deutschmann H; Dagn K; Exeli AK; Kopp P; Porsch P; Maurer B; Studnicka M; Sedlmayer F
Strahlenther Onkol; 2017 Apr; 193(4):315-323. PubMed ID: 28116446
[TBL] [Abstract][Full Text] [Related]
8. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
9. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.
Socinski MA; Morris DE; Halle JS; Moore DT; Hensing TA; Limentani SA; Fraser R; Tynan M; Mears A; Rivera MP; Detterbeck FC; Rosenman JG
J Clin Oncol; 2004 Nov; 22(21):4341-50. PubMed ID: 15514375
[TBL] [Abstract][Full Text] [Related]
10. Three-times-daily radiotherapy with induction chemotherapy in locally advanced non-small cell lung cancer. Feasibility and toxicity study.
Catalano G; Jereczek-Fossa BA; De Pas T; Leon ME; Cattani F; Spaggiari L; Veronesi G; de Braud F; Orecchia R
Strahlenther Onkol; 2005 Jun; 181(6):363-71. PubMed ID: 15925978
[TBL] [Abstract][Full Text] [Related]
11. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
Cicenas S; Zaliene A; Atkocius V
Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
[TBL] [Abstract][Full Text] [Related]
12. Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.
Bahri S; Flickinger JC; Kalend AM; Deutsch M; Belani CP; Sciurba FC; Luketich JD; Greenberger JS
Radiat Oncol Investig; 1999; 7(5):297-308. PubMed ID: 10580899
[TBL] [Abstract][Full Text] [Related]
13. Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117.
Bradley JD; Bae K; Graham MV; Byhardt R; Govindan R; Fowler J; Purdy JA; Michalski JM; Gore E; Choy H
J Clin Oncol; 2010 May; 28(14):2475-80. PubMed ID: 20368547
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.
Lee SW; Choi EK; Lee JS; Lee SD; Suh C; Kim SW; Kim WS; Ahn SD; Yi BY; Kim JH; Noh YJ; Kim SS; Koh Y; Kim DS; Kim WD
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):996-1004. PubMed ID: 12829135
[TBL] [Abstract][Full Text] [Related]
15. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
16. Dose escalated, hypofractionated radiotherapy using helical tomotherapy for inoperable non-small cell lung cancer: preliminary results of a risk-stratified phase I dose escalation study.
Adkison JB; Khuntia D; Bentzen SM; Cannon GM; Tome WA; Jaradat H; Walker W; Traynor AM; Weigel T; Mehta MP
Technol Cancer Res Treat; 2008 Dec; 7(6):441-7. PubMed ID: 19044323
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
[TBL] [Abstract][Full Text] [Related]
18. A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04).
Bradley JD; Scott CB; Paris KJ; Demas WF; Machtay M; Komaki R; Movsas B; Rubin P; Sause WT
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1173-9. PubMed ID: 11955727
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy for lung cancer: target splitting by asymmetric collimation enables reduction of radiation doses to normal tissues and dose escalation.
Wurstbauer K; Deutschmann H; Kranzinger M; Merz F; Rahim H; Sedlmayer F; Kogelnik HD
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):333-41. PubMed ID: 10760428
[TBL] [Abstract][Full Text] [Related]
20. High-dose conformal radiotherapy for patients with stage III non-small-cell lung carcinoma.
Nakayama H; Satoh H; Kurishima K; Ishikawa H; Tokuuye K
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):645-50. PubMed ID: 20869582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
